Condition
High Grade Serous Ovarian Carcinoma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Active Not Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07115043Phase 1Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT05827614Phase 1Active Not Recruiting
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT04099277Phase 1Terminated
A Study of LY3435151 in Participants With Solid Tumors
Showing all 3 trials